Of interest, in the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) analysis, there was a non-significant association with reduced recurrences with adjuvant tamoxifen in the ER-/PgR+ phenotype despite this group being considered ER-negative [1]. The gene discussed is PGR; the disease is breast carcinoma.